
GERN • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold GERN in your mock portfolio yet.
Geron remains unprofitable, as indicated by its negative EPS and PE ratio. The current financial profile is typical of a development-stage biotech: cash-burning with no clear profitability in the near term based on the provided metrics.
The stock is trading modestly above its 200-day moving average with a small 3.8% gain over the last month, indicating a slightly constructive but not strongly bullish trend. An RSI near 36 suggests the stock is weak but not yet oversold, pointing to cautious sentiment rather than capitulation or strong momentum.
Alternative data shows early signs of strengthening corporate activity and engagement. Job openings are up sharply, and LinkedIn followers are growing, which together suggest organizational scaling and gradually rising investor and professional interest.
Overall, Geron presents a mixed picture: financially it remains loss-making, while the stock trades slightly above its long-term average with subdued momentum. However, alternative data hints at organizational growth and rising attention, which could be constructive if supported by future clinical or regulatory catalysts.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: